IMM27M
Phase 1Small molecule
IMM27M is one of 39 small molecule programs targeting Toxicity. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
223 competitors in Toxicity
#DrugCompanyPhaseTrials
1Cytotec
PfizerPhase 3
Erbitux
IImclone
Phase 3
Coly-Mycin M
PParkedale
Phase 3
Mucosta
OtsukaPhase 3
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Paracetamol
GSKPhase 3
Cysteine Hydrochloride
NovartisPreclinical
Colistin Sulfomethate
MMahidol University
Phase 3
Cellcept
NovartisPreclinical
Afinitor
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMM27M. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details